Previous 10 | Next 10 |
-- Study highlights need to address varying levels of effective disease management, and the associated feelings of uncertainty, stress and isolation across eight European countries – -- Country-specific data show German respondents experience highest levels of anxiety, more than...
Aimmune Therapeutics (AIMT) is a newly commercial-stage biopharma developing a line of drugs designed to desensitize patients with common food allergies. Aimmune's first drug, Palforzia, was approved by the FDA to treat peanut allergies at the end of January 2020 and had just gotten out on the...
"I refuse to answer that question on the grounds that I don't know the answer. " - Douglas Adams The market is starting the new trading week on the right foot today. Investors are encouraged by more economies restarting, progress on the Covid-19 containment front and the latest vaccine n...
This January, the U.S. Food and Drug Administration (FDA) approved the first biologic for the treatment of peanut allergies in children and adolescents. The drug is called Palforzia and is marketed by Aimmune Therapeutics (NASDAQ: AIMT) . Expectations for Palforzia are high, as many analysts...
Genfit SA (NASDAQ: GNFT ) -67% after elafibranor flunks NASH study. More news on: Genfit SA, California Resources Corporation, Rand Capital, Stocks on the move, , Read more ...
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt, will participate in a fireside chat at the RBC Capital Markets 20...
Image source: The Motley Fool. Aimmune Therapeutics Inc (NASDAQ: AIMT) Q1 2020 Earnings Call May 11, 2020 , 4:30 p.m. ET Operator Continue reading
Aimmune Therapeutics, Inc. (AIMT) Q1 2020 Earnings Conference Call May 11, 2020 16:30 ET Company Participants DeDe Sheel - Vice President, Investor Relations Jayson Dallas - President & Chief Executive Officer Andrew Oxtoby - Chief Commercial Officer Eric Bjerkholt - Chief ...
Aimmune Therapeutics (NASDAQ: AIMT ): Q1 Non-GAAP EPS of -$1.03 beats by $0.15 ; GAAP EPS of -$1.34 misses by $0.16 . Revenue of $0.58M misses by $0.76M . Press Release More news on: Aimmune Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
Continues to be launch ready for PALFORZIA TM EU and Swiss regulatory reviews for PALFORZIA remain on schedule Uninterrupted drug supply for all ongoing clinical trials $371.6 million cash, cash equivalents and investments on-hand and implementing numerous ca...
News, Short Squeeze, Breakout and More Instantly...
Aimmune Therapeutics Inc. Company Name:
AIMT Stock Symbol:
NASDAQ Market:
— Majority of Patients Experienced Low Rates of Adverse Events, Which Declined in Frequency and Severity with Continued Treatment — — Systemic Allergic Reactions and Epinephrine Use Were Low and Decreased Over Time — Aimmune Therapeutics, ...
-- Peanut Allergy is One of the Most Common Food Allergies in Europe -- -- Up to 1.6% of European Children Live with Potentially Life-Threatening Peanut Allergy -- Aimmune Therapeutics, Inc., a Nestlé Health Science Company, today announced that the European Com...
VEVEY, Switzerland , Sept. 14, 2020 /PRNewswire/ -- Société des Produits Nestlé S.A. ("Nestlé") announced that its wholly-owned subsidiary, SPN Merger Sub, Inc. ("Purchaser"), is commencing today a cash tender offer to purchase all of the outstanding shares of common s...